Skip to main content

Conference Correspondent

Conference Correspondent, ASH 2016 - Multiple Myeloma

Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients

Conference Correspondent, ASH 2016 - Multiple Myeloma

Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Pomalidomide and Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Salvage Use of Ibrutinib After allo-HSCT for B-Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Society for Blood and Marrow Transplantation (SFGM-TC), and the EBMT Chronic Malignancy and Lymphoma Working Parties

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

CLL2-BIG – A Novel Treatment Regimen of Bendamustine Followed by GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Trial

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multicenter Study of 683 US Patients

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft-versus-Host Disease (cGVHD) After Failure of Corticosteroids

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL

Page 5 of 8
Results 41 - 50 of 79